You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study

Citation Tools

Article menu

Download PDFPDF

Gastroenterology and hepatology
Protocol
Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Matsuoka K, Nagano K, Nagasaki S, et al
Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
BMJ Open 2022;12:e060081. doi: 10.1136/bmjopen-2021-060081